Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients.

MLA

Arisi, Ivan, et al. “Cladribine and Ocrelizumab Induce Differential MiRNA Profiles in Peripheral Blood Mononucleated Cells from Relapsing-Remitting Multiple Sclerosis Patients.” Frontiers in Immunology, vol. 14, Dec. 2023, p. 1234869. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1234869.

APA

Arisi, I., Malimpensa, L., Manzini, V., Brandi, R., Gosetti di Sturmeck, T., D’Amelio, C., Crisafulli, S., Ferrazzano, G., Belvisi, D., Malerba, F., Florio, R., Pascale, E., Soreq, H., Salvetti, M., Cattaneo, A., D’Onofrio, M., & Conte, A. (2023). Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients. Frontiers in Immunology, 14, 1234869. https://doi.org/10.3389/fimmu.2023.1234869

Chicago

Arisi, Ivan, Leonardo Malimpensa, Valeria Manzini, Rossella Brandi, Tommaso Gosetti di Sturmeck, Chiara D’Amelio, Sebastiano Crisafulli, et al. 2023. “Cladribine and Ocrelizumab Induce Differential MiRNA Profiles in Peripheral Blood Mononucleated Cells from Relapsing-Remitting Multiple Sclerosis Patients.” Frontiers in Immunology 14 (December): 1234869. doi:10.3389/fimmu.2023.1234869.